Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.36 |
| ▸ | BLM | P54132 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174381 | 1.00 | CHRM2 (0.41) | CHRM2LMNATHRBKMT2AMEN1 | |
| SCHEMBL146038 | 1.00 | CHRM2 (0.41) | CHRM2LMNATHRBKMT2AMEN1 | |
| SCHEMBL27220640 | 1.00 | CHRM2 (0.41) | CHRM2LMNATHRBKMT2AMEN1 | |
| SCHEMBL2125590 | 1.00 | CHRM2 (0.41) | CHRM2LMNATHRBKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL6157108 | 0.98 | CHRM2 (0.40) | CHRM2LMNATHRBKMT2AMEN1 | |
| SCHEMBL838138 | 0.98 | CHRM2 (0.38) | CHRM2LMNATHRBKMT2AMEN1 | |
| Ammonia Solution, Strong SCHEMBL22716834 | 0.96 | CHRM2 (0.37) | CHRM2LMNATHRBKMT2AMEN1 | |
| SCHEMBL838329 | 0.92 | KMT2A (0.36) | LMNATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL22321638 | 0.84 | MEN1 (0.31) | KMT2AMEN1 | |
| SCHEMBL5452674 | 0.83 | CHRM2 (0.42) | CHRM2LMNATHRBKMT2ABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120093767-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
| WO-2011139513-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093767-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, SLC10A1, HCCS | CHRM2 4552/4885LMNA 3006/4885THRB 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.